Vidofludimus calcium reduced NfL levels in progressive MS patients
Vidofludimus calcium (IMU-838), an investigational oral therapy being developed byĀ Immunic Therapeutics for all types of multiple sclerosis (MS), has demonstrated neuroprotective effects in people with progressive forms of the disease, interim clinical trial data show. The experimental therapy was associated with reductions in neurofilament light chain (NfL)…